Teijin Pharma Limited

Merck Sharp + Dohme Corp.

Naoko Namiki

Hiroshi H Eguchi

Akira Tanokura

Takashi Murakami

Jeanne E Baker

Carl Mieczkowski

Sophie Parmentier Batteur

Angela Marie Jablonski

Daniel Stephen Malashock

Gopalan (Raghu) Raghunathan

Kenichiro Takagi

Satoshi Yamamura

Hirotsugu Kato

Hirofumi Higuchi

Tomoyo Takeo

Daisuke Ishikawa

Masayo Ohori

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

Anti-IGF-I receptor humanized antibody

The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.

Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies

Growing community of inventors

Tokyo, Japan

Naoko Namiki